Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm

Antioxidants and Redox Signaling

Volumn 11, Issue 1, 2009, Pages 47-58

  Gordillo, Gayle ^a,c   Fang, Huiqing ^a   Khanna, Savita ^a   Harper, Justin ^c   Phillips, Gary ^b   Sen, Chandan K ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLUEBERRY EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLUEBERRY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CHILD CARE; CHILDHOOD CANCER; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HEMANGIOENDOTHELIOMA; IN VITRO STUDY; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOFT TISSUE TUMOR; TUMOR GROWTH; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; BLUEBERRY PLANT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HEMANGIOENDOTHELIOMA; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIERS ESTIMATE; MICE; MICE, INBRED STRAINS; PHYTOTHERAPY; PLANT EXTRACTS; SURVIVAL ANALYSIS; TUMOR BURDEN;

MURINAE; MUS; VACCINIUM;

EID: 55249101979     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2008.2150     Document Type: Article

References (66)

1. Albini A, Morini M, D'Agostini F, Ferrari N, Campelli F, Arena G, Noonan DM, Pesce C, and De Flora S. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 61: 8171-8178, 2001.
2. Amann B, Pearbo F, Wirger A, Hugenschmidt H, and Schultze-Seeman W. Urinaryl levels of monocyte chemoattractant protein-1 correlate with tumor stage and grade in patients wih bladder cancer. Br J Urol 82: 118-121, 1998.
3. Atalay M, Gordillo G, Roy S, Rovin B, Bagchi D, Bagchi M, and Sen CK. Anti-angiogenic property of edible berry in a model of hemangioma. FEBS Lett 544: 252-257, 2003.
4. Biswas SK, Sica A, and Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180: 2011-2017, 2008.
5. Bost F, McKay R, Bost M, Potapova O, Dean NM, and Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Molecular and cellular biology 19: 1938-1949, 1999.
6. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L, Flavell RA, and Dong Z. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 61: 3908-3912, 2001.
7. Chen YR, Wang W, Kong AN, and Tan TH. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem 273: 1769-1775, 1998.
8. Ding M, Lu Y, Bowman L, Huang C, Leonard S, Wang L, Vallyathan V, Castranova V, and Shi X. Inhibition of AP-1 and neoplastic transformation by fresh apple peel extract. J Biol Chem 279: 10670-10676, 2004.
9. Dong Z, Birrer MJ, Watts RG, Matrisian LM, and Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Nat Acad Sci USA 91: 609-613, 1994.
10. Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM, and Colburn NH. A dominant negative mutant of jun blocking 12-O- tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinogen 19: 204-212, 1997.
11. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, and Cross-Doersen DE. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Diff 7: 351-359, 1996.
12. Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M, Bilter GK, and Stein B. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharmacol Exp Ther 313: 325-332, 2005.
13. Folkman J, Mulliken J, and Ezekowitz R. Angiogenesis and hemangiomas. In: Surgery of Infants and Children: Scientific Principles and Practice, edited by Oldham K. Philadelphia: Lippincott-Raven, 1997, p. 569-584.
14. Gordillo G, Onat D, Stockinger M, Roy S, Atalay M, Beck M, and Sen C. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am J Physiol (Cell) 287: C866-873, 2004.
15. Gordillo GM, Atalay M, Roy S, and Sen CK. Hemangioma model for in vivo angiogenesis: inducible oxidative stress and MCP-1 expression in EOMA cells. Methods Enzymol 352: 422-432, 2002.
16. Harper S and LoGrasso P. Inhibitors of JNK signaling pathway. Drugs of the Future 26: 957-973, 2001.
17. Heasley LE and Han S-Y. JNK regulation of oncogenesis. Mol Cells 21: 167-173, 2006.
18. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, and Kainz C. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81: 855-859, 1999.
19. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, and Anderson K. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 22: 8797-8801, 2003.
20. Hoak JC, Warner ED, Cheng HF, Fry GL, and Hankenson RR. Hemangioma with thrombocytopenia and microangiopathic anemia (Kasabach-Merritt syndrome): an animal model. J Lab Clin Med 77: 941-950, 1971.
21. Hou DX, Kai K, Li JJ, Lin S, Terahara N, Wakamatsu M, Fujii M, Young MR, and Colburn N. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms. Carcinogenesis 25: 29-36, 2004.
22. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 18: 6087-6093, 1999.
23. Isik F, Rand R, Gruss J, Benjamin D, and Alpers C. Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 61: 71-76, 1996.
24. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, and Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science New York 275: 218-220, 1997.
25. Kahkonen MP, Hopia AI, and Heinonen M. Berry phenolics and their antioxidant activity. J Agric Food Chem 49: 4076-4082, 2001.
26. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270: 16483-16486, 1995.
27. Koyama J, Morita I, Kobayashi N, Konoshima T, Takasaki M, Osakai T, and Tokuda H. Correlation between oxidation potentials and inhibitory effects on Epstein-Barr virus activation of flavonoids. Cancer Lett 263: 61-66, 2008.
28. Lannutti B, Gately S, Quevedo M, Soff G, and Paller A. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-5280, 1997.
29. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, and Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629, 1996.
30. Leppa S and Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18: 6158-6162, 1999.
31. Lewis CE, De Palma M, and Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67: 8429-8432, 2007.
32. Li JJ, Dong Z, Dawson MI, and Colburn NH. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res 56: 483-489, 1996.
33. Lo YY, Wong JM, and Cruz TF. Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. J Biol Chem 271: 15703-15707, 1996.
34. Martin T, Cardelli P, Parry G, Felts K, and Cobb R. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends upon the cooperative action of NF-kappaB and AP-1. Eur J Immunol 27: 1091-1097, 1997.
35. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, and Van Den Berg CL. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23: 596-604, 2004.
36. Nateri AS, Spencer-Dene B, and Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437: 281-285, 2005.
37. O'Reilly M, Brem H, and Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Ped Surg 30: 325-330, 1995.
38. Obeso J, Weber J, and Auerbach R. A hemangioendothelioma-derived cell line: its use as a model for the study of endothelial cell biology. Lab Invest 63: 259-269, 1990.
39. Paller AS. Responses to anti-angiogenic therapies. J Invest Dermatol Symp Proc 5: 83-86, 2000.
40. Park HS, Park E, Kim MS, Ahn K, Kim IY, and Choi EJ. Selenite inhibits the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism. J Biol Chem 275: 2527-2531, 2000.
41. Pataki T, Bak I, Kovacs P, Bagchi D, Das DK, and Tosaki A. Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts. Am J Clin Nut 75: 894-899, 2002.
42. Patel R, Bartosch B, and Blank JL. p21WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression. J Cell Sci 111: 2247-2255, 1998.
43. Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, and Sturgill TW. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10: 885-892, 1991.
44. Pool-Zobel BL, Bub A, Schroder N, and Rechkemmer G. Anthocyanins are potent antioxidants in model systems but do not reduce endogenous oxidative DNA damage in human colon cells. Eur J Nut 38: 227-234, 1999.
45. Risse-Hackl G, Adamkiewicz J, Wimmel A, and Schuermann M. Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins. Oncogene 16: 3057-3068, 1998.
46. Rogerio AP, Kanashiro A, Fontanari C, da Silva EV, Lucisano-Valim YM, Soares EG, and Faccioli LH. Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. Inflamm Res 56: 402-408, 2007.
47. Roy S, Khanna S, Alessio HM, Vider J, Bagchi D, Bagchi M, and Sen CK. Anti-angiogenic property of edible berries. Free Rad Res 36: 1023-1031, 2002.
48. Roy S, Venojarvi M, Khanna S, and Sen CK. Simultaneous detection of tocopherols and tocotrienols in biological samples using HPLC-coulometric electrode array. Methods Enzymol 352: 326-332, 2002.
49. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, and Spiegelman BM. c-fos is required for malignant progression of skin tumors. Cell 82: 721-732, 1995.
50. Sage H and Bornstein P. Endothelial cells from umbilical vein and hemangioendothelioma secrete basement mebrane largely to the exclusion of interstitial procollagens. Arteriosclerosis 2: 27-36, 1982.
51. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, and Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92: 1085-1091, 2001.
52. Semenza GL. A new weapon for attacking tumor blood vessels. New Eng J Med 358: 2066-2067, 2008.
53. Sen CK, Khanna S, Roy S, and Packer L. Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells. J Biol Chem 275: 13049-13055, 2000.
54. Serafini M, Laranjinha JA, Almeida LM, and Maiani G. Inhibition of human LDL lipid peroxidation by phenol-rich beverages and their impact on plasma total antioxidant capacity in humans. J Nutr Biochem 11: 585-590, 2000.
55. Shim J, Lee H, Park J, Kim H, and Choi EJ. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381: 804-806, 1996.
56. Shin EY, Kim SY, and Kim EG. c-Jun N-terminal kinase is involved in motility of endothelial cell. Exp Mol Med 33: 276-283, 2001.
57. Sica A, Wang J, Collota F, DeJana E, Montovani A, Larsen C, Zachariae C, and Matsushima K. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol 144: 3034-3038, 1990.
58. Surh YJ, Kundu JK, Na HK, and Lee JS. Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr 135: 2993S-3001S, 2005.
59. Szabo ME, Gallyas E, Bak I, Rakotovao A, Boucher F, de Leiris J, Nagy N, Varga E, and Tosaki A. Heme oxygenase-1-related carbon monoxide and flavonoids in ischemic/reperfused rat retina. Invest Ophthalmol Vis Sci 45: 3727-3732, 2004.
60. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, and Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Nat Cancer Inst 87: 293-298, 1995.
61. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, and Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6: 3282-3289, 2000.
62. Wang C, Quevedo ME, Lannutti BJ, Gordon KB, Guo D, Sun W, and Paller AS. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J Invest Dermatol 112: 775-781, 1999.
63. Wang N, Verna L, Hardy S, Forsayeth J, Zhu Y, and Stemerman MB. Adenovirus-mediated overexpression of c-Jun and c-Fos induces intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol 19: 2078-2084, 1999.
64. Warner ED, Hoak JC, and Fry GL. Hemangioma, thrombocytopenia, and anemia. The Kasabach-Merritt syndrome in an animal model. Arch Pathol 91: 523-528, 1971.
65. Yamamoto Y and Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clinl Invest 107: 135-142, 2001.
66. Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R, and Colburn N. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Nat Acad Sci USA 96: 9827-9832, 1999.